Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | QPCT | Q16769 | 2/20 | 0.39 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL739311 | 0.98 | SMN1; SMN2 (0.39) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL15711438 | 0.96 | SMN1; SMN2 (0.42) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL7392775 | 0.92 | SMN1; SMN2 (0.42) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL29079327 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL27660736 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL28555792 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL4359682 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL7214615 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL28467045 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2PDPK1CA12PARP1ALOX15 | |
| Benzimidazole SCHEMBL461969 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2PDPK1CA12PARP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113512203-B | Preparation method of chiral photosensitive metal organic framework material | 江苏师范大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-113512203-A | Preparation method of chiral photosensitive metal organic framework material | 江苏师范大学 | 2021-10-19 | — | — | CN | disclosed |
| CN-105793258-B | The crystalline salt form and its application of benzimidazole cycle compound | 爱杜西亚药品有限公司 | 2018-12-28 | — | — | CN | disclosed |
| CN-106565644-A | 3- alkyl-5-hydroxy-4-aryl furanone derivative and preparation method thereof | 上海大学 | 2017-04-19 | — | — | CN | disclosed |
| EP-1597229-B1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK SERONO SA (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-20070037806-A1 | Such as (3EZ,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime which blocks oxytocin receptors; for prevention and/or treatment of preterm labor, premature birth or dysmenorrhea | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-02-15 | — | — | US | disclosed |
| EP-1597229-A2 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004076407-A2 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037806-A1 | Such as (3EZ,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime which blocks oxytocin receptors; for prevention and/or treatment of preterm labor, premature birth or dysmenorrhea | OXTR, PRLHR, OPRL1 | SMN1; SMN2 1432/4885PDPK1 3053/4885CA12 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.